AbbVie's Lutikizumab Shows Promise in Treating Moderate to Severe Hidradenitis Suppurativa

MEEFRO January 11, 2024

0 0 Less than a minute

Lutikizumab (ABT-981) will advance to a Phase III trial in patients with moderate to severe hidradenitis suppurativa who previously failed anti-tumor necrosis factor therapy.

Source link
#AbbVie039s #Lutikizumab #Shows #Promise #Treating #Moderate #Severe #Hidradenitis #Suppurativa